Zimbabwe has turned down a major American healthcare agreement worth 367 million US dollars (272 million pounds) over five years over the United States' insistence on sensitive data.
The decision became public following a internal memorandum from December was disclosed, indicating that Head of State Emmerson Mnangagwa deemed the deal was "lopsided".
A government representative has since clarified that the US was seeking genetic material for scientific study and profit while was not willing to guarantee the resulting advantages from any future medical innovations.
"We will now turn to the difficult and regrettable task of winding down our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the United States had provided over $1.9bn in health funding to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has appealed for more negotiations to find a agreement acceptable to both sides so the country's vital HIV treatment initiative can be sustained.
Broader Implications
This rejection follows a comparable case in Kenya, where a high court halted a related deal with the US following legal challenges were raised about the safety of Kenyans' medical information.
Since returning to the presidency recently, US President Donald Trump has slashed overseas assistance and shut down the US Agency for International Development (USAID).
The agency had managed aid for the US government, but Trump claimed its spending was "wasteful" and his government was seeking direct bilateral deals to boost openness and accountability.
According to reports, Sixteen nations in Africa have so far agreed to these new agreements, constituting over $18.3bn in committed funds.
Details of the Rejected Agreement
The money for Zimbabwe would have gone towards "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this cooperation could have provided significant benefits for the people of Zimbabwe, especially the 1.2 million men, women and children presently on antiretroviral therapy via American-funded programmes," the Ambassador said.
However, government spokesperson Nick Mangwana said the proposed deal was "asymmetrical".
"The proposal required Zimbabwe to provide its biological resources and data indefinitely, with no equivalent assurance of benefiting from any medical innovations – such as vaccines, diagnostics, or treatments – that could be developed from that provided information," Mangwana explained.
"In essence, our nation would supply the raw materials for scientific discovery with no certainty that the end products would be available to our citizens should a new health crisis arise."
Sovereignty and Global Health
Mangwana further noted that the US's withdrawal from the global health body and its push of one-on-one health agreements were undermining structures already set up through the international organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing scheme designed to manage future pandemics.
"This system is intended to guarantee that when a nation contributes its samples, the benefits – including medicines and cures – are distributed fairly, not commercialised solely by those with the funds to develop them."
These objections regarding the US deal "must not be interpreted as hostility towards the US," he added.
"We are open to continued dialogue with our US partners on how subsequent collaboration might be arranged in a manner that respects the sovereignty and dignity of each country."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it understood the official position, but urged that talks need to persist considering much of the nation's Aids initiatives were funded by international support.
"If technical issues exist, including those relating to data governance or implementation frameworks, these can often be resolved through detailed discussion and negotiated safeguards," the group said.
The situation highlights the continuing challenges between receiving much-needed international aid and protecting local interests in an ever more data-driven world.